Bibliography
- NAGASE H, WOESSNER JF: Matrix metalloproteinases. J. Biol. Chem. (1999) 274(30:21491–21494.
- •An excellent mini-review of the MMPs.
- CAWSTON T: Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol. Ther. (1996) 70(3):163–182.
- CHAMBERS AF, MATRISIAN LM: Changing views of the role of matrix metalloproteinases in metastasis. J. Nail Cancer Inst. (1997) 89(17):1260–1270.
- CELENTANO DC, FRISHMAN WH: Matrix metallo-proteinases and coronary artery disease: a novel therapeutic target. J. Clin. Pharmacol. (1997) 37:991–1000.
- SPINALE FG, COKER ML, KROMBACH SR et al: Matrixmetalloproteinase inhibition during the development of congestive heart failure-effects on left ventricular dimensions and function. Circulation Research (1999) 85(4):364–376.
- YONG VW: The potential use of MMP inhibitors to treat CNS diseases. Exp. Opin. Invest. Drugs (1999) 8(3):255–268.
- OVERALL CM, WIEBEN OW, THONARD JC: Demonstra-tion of tissue collagenase activity in vivo and its relationship to inflammation severity in human gingiva. J. Periodontal Res. (1987) 22:81–88.
- KOIVUNEN E, ARAP W, VALTANEN H et al.: Tumortargeting with a selective gelatinase inhibitor. Nature Biotechnology (1999) 17:768–774.
- MAEKAWA R, MAKI H, YOSHIDA H et al.: Correlation ofantiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. (1999) 59:1231–1235.
- WHITTAKER M, FLOYD CD, BROWN P, GEARING AJH: Design and therapeutic application of matrix metallo-proteinase inhibitors. Chem. Rev. (1999) 99:2735–2776.
- •A comprehensive review of small molecule MMP inhibitors.
- BROWN PD: Clinical studies with matrix metalloprote- inase inhibitors. APMIS (1999) 107:174–180.
- WOOD ND, AITKEN M, DURSTON S, HARRIS S, MCCLEL-LAND GR, SHARPS: Cartilage protective agent (CPA) Ro 32-555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. Agents Actions Suppl. (1998) 49:49–55.
- MACPHERSON LI BAYBURT EK, CAPPARELLI MP et al.: Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. (1997) 40:2525–2532.
- SHALINSKY DR, BREKKEN J, ZOU H et al.: Broadantitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. Sci. (1999) 878:61–72.
- SKOTNICKI JS, LEVIN JI, ZASK A, KILLAR LM: Matrixmetalloproteinase inhibitors. In: Metalloproteinases as targets for anti-inflammatory drugs. Bottomley KMK, Bradshaw D, Nixon JS (Eds.), Birkhauser Verlag, Basel, Switzerland (1999):17–57.
- BAY-12-9566. Drugs of the Future (1999) 24 (1):16–21.
- NEMUNAITIS J, POOLE J, PRIMROSE J: Combinedanalysis of studies of the effects of the matrix metallo-proteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer term studies. Clin. Cancer Res. (1998) 4:1101–1111.
- ALEX SHIMMINGS: Bayer and Agouron compete in MMPinhibitor field. Scrip (1998) 2349:20–21.